In the race to find the next great product in this family of plant molecules, Berkeley-based Demetrix announced today that it has commenced 15,000-liter demo-scale fermentation production of CBG, the first rare cannabinoid it will take to market. Demetrix CEO Jeff Ubersax says that CBG (also known as cannabigerol) is among the first cannabinoids in the chemical pathway that plants make. “This is a cannabinoid that most of the other cannabinoids are derived from,” says Ubersax. Based on its early testing of the molecule, Demetrix believes CBG has some interesting potential applications beyond current uses. “Cannabinoids fall into that bucket really, really well.”The future is bright for the small and mightyUbersax is enthusiastic not just for Demetrix and the cannabinoids industry, but for all of synthetic biology.

Source: Forbes September 03, 2020 18:11 UTC